Stabilization of virus protein structure and nucleic acid integrity is challenging yet essential to preserve the transcriptional competence of live recombinant viral vaccine vectors in the absence of a cold chain. When coupled with needle-free skin delivery, such a platform would address an unmet need in global vaccine coverage against HIV and other global pathogens. Herein, we show that a simple dissolvable microneedle array (MA) delivery system preserves the immunogenicity of vaccines encoded by live recombinant human adenovirus type 5 (rAdHu5 
Stabilization of virus protein structure and nucleic acid integrity is challenging yet essential to preserve the transcriptional competence of live recombinant viral vaccine vectors in the absence of a cold chain. When coupled with needle-free skin delivery, such a platform would address an unmet need in global vaccine coverage against HIV and other global pathogens. Herein, we show that a simple dissolvable microneedle array (MA) delivery system preserves the immunogenicity of vaccines encoded by live recombinant human adenovirus type 5 (rAdHu5 I nfection with HIV, malaria, and tuberculosis represents a global public health challenge. Candidate vaccines based on live recombinant viral vectors such as adenovirus (Ad), CMV, and poxvirus show promise through their ability to induce strong T-cell immunity (1) (2) (3) . However, live vaccines are thermolabile, with loss in potency and safety in the absence of continuous cold chain storage and transport. Lyophilization has been used to stabilize virus/vector infectivity (4, 5) , yet, in resource limited settings, this approach is constrained by the need for sterile reconstitution, safe injection, and trained staff. This situation creates risks of blood borne disease transmitted from contaminated needles and syringes and, once reconstituted, lyophilized vaccines rapidly loose potency, incurring wastage and increased cost (5) , highlighting a critical unmet need, for vaccines that enable ease of administration with long-term viral vector thermostability. Therefore, it would be invaluable to combine the heat stability of a dry vaccine with technology that introduced "live" vaccine antigens (Ags) by needle-free administration that had the capacity to harness the Ag presenting capacity of tissue resident dendritic cells (DCs) in the skin.
Developments in microfabrication technology have enabled ultrasharp, micrometer-scale projections to penetrate the skin, containing lyophilized vaccine coated on metallic structures or encapsulated within dissolvable polymers (6) (7) (8) . Designs under evaluation have largely been restricted to nonlive vaccine platforms (6, (8) (9) (10) . However, for HIV, induction of high frequency protective CD8
+ T-cell responses will require high levels of Ag expression in the context of a potent inflammatory response that has been achieved by live recombinant Ad vectors in preclinical models (1) . However, the capacity of this new generation of live recombinant vaccines to prime CD8 + T cells as dried microneedle arrays (MAs) via the skin has largely been unexplored. Although intense interest has focused on the physical parameters of microneedle fabrication (7, 11) + T Cells via Skin Delivery. We first determined whether rAdHu5 vectors could be dried at room temperature and stored without loss of immunogenicity by using sodium carboxymethylcellulose (Na-CMC), a biocompatible, mechanically strong, highly water soluble polymer (14) suitable for microneedle fabrication and sucrose, an established protein stabilizer. A rAdHu5 vector expressing chicken ovalbumin (OVA) air dried and stored under desiccation at 25°C up to 1 mo demonstrated no statistically significant loss in immunogenicity, determined by K b /SIINFEKL pentamer staining as a measurement of CD8 + T-cell induction to an immunodominant OVA epitope, when reconstituted and injected s.c. in B6 mice compared with the control virus stored at −80°C that contained an equivalent virus titer and was injected in parallel (Fig. 1A) . To evaluate the potential of the dried rAdHu5 formulation in a needle-free delivery system, dissolvable microneedles (1,500 μm in length, 44 per array) were fabricated within a silicone template. The Na-CMC-sucrose matrix containing virus and tetramethyl rhodamine (TR) dextran (for visualization) formed the needle tips ( Fig. 1 B and C) . Mechanical strength was added by layering a second matrix [12% (wt/vol) Na-CMC, 4.8% (wt/vol) lactose] creating the needle shaft and applying a premade membrane [8% (wt/vol) Na-CMC, 0.8% lactose) to the needle base. Each array contained an average of 7.8 × 10 8 virus particles (vp) of rAdHu5 vector determined by virus recovery. The MAs dissolved within 5 min of application by gentle pressure to the skin of B6 mice and, after removal, were reduced by approximately two-thirds in length (Fig. 1C) , depositing on average 4.3 × 10 8 vp of rAdHu5 vector in the skin. At day 10 after immunization, a high frequency of K b /SIINFEKL pentamer-specific CD8 + T cells were tracked in the systemic compartment (blood and spleen) and also mucosal tissues [mesenteric lymph node (MLN) and Peyer's patches], exemplified in Fig. 1D . To assess their function, CD8 + T cells from the spleen were analyzed by multiparameter flow cytometry for intracellular IL-2, TNF-α, and IFN-γ after ex vivo stimulation with OVA [257] [258] [259] [260] [261] [262] [263] [264] (Fig.  1E) or IFN-γ, TNF-α, and CD107a (Fig. S1 ). Consistent with previous human adenovirus type 5 (AdHu5) vaccine immunization studies by conventional i.m. injection (15, 16) , the MAs induced robust IFN-γ and TNF-α-producing CD8 + T cells with low levels of intracellular IL-2 (Fig. 1E) , and also high-frequency CD8 + T cells with up-regulation of CD107a that also secreted IFN-γ or TNF-α (Fig. S1 ). These results indicate that a single immunization with a dried live rAdHu5 vectored MA retained the capacity to induce multifunctional CD8 + T cells. + T-cell expansion was determined in blood at day 13 and, also, in spleen, MLN, and Peyer's patches at day 14. The frequency of SIINFEKL-specific CD8 + T cells induced by MA immunization when cross-compared with each other route of immunization was statistically indistinguishable ( Fig. 2A) and was also comparable with the i.m. route at a lower vector dose (Fig. S2) . Interestingly, a trend toward an increased frequency of SIINFEKL-specific CD8 + T cells induced in Peyer's patches of MA primed relative to the i.m. or s.c. primed mice was observed ( Fig. 2A) . Consistent with this observation, splenocytes from MA.-primed mice expressed a significant increase in the α4β7 mucosal homing marker on SIINKFEKL-specific CD8 killing in vivo is regarded as essential for a successful HIV vaccine (17) . Therefore, mice primed with rAdHu5 HIV-1 CN54 gag by dried MA or by i.d. injection were challenged i.v. on day 14 with carboxyfluorescein succinimidyl ester (CFSE)-labeled syngeneic targets pulsed with HIV-1 CN54 gag 309-318 peptide and control targets and cytotoxicity were analyzed after 15 h by flow cytometry. Comparable and robust in vivo killing was observed in spleen, inguinal, and MLN of mice immunized by the MA or i.d. route (Fig.  3C ). Hence, a dried rAdHu5 HIV-1 gag MA vaccine generated robust CD8 + effector T-cell responses of similar immunogenicity to the cognate vaccine in liquid suspension by i.d. injection.
Rapid Dermal Penetration, Dissolution and Dissemination Characterize
Air-Dried MA Delivery. We next sought to determine the early events after MA application to the skin, because such information is germane to understanding their mechanism of delivery and safety. To track entry and dissolution in skin, MAs were fabricated to include FITC or TR-dextran in the matrix. Immunofluorescence microscopy of frozen mouse skin sections (dissected 30 min after application to the dorsal surface) confirmed disruption of the epidermis and FITC-dextran lining the perforation site (Fig. S4) . Deeper in the dermis, at sites distant from the entry point, a FITC-dextran deposition also was shown, seemingly reflecting diffusion locally within 30 min (Fig. S4 ). Intravital confocal microscopy and Langerin-EGFP reporter mice were used to visualize the dynamics of MA penetration and TR-dextran (MA content) release in relation to DCs mobilization in back skin. Circular punctures within the LC network of the epidermis (20 μm below the surface) created by MA entry were observed 5 min after application (Fig. 4A , Top and Middle). At the same time within the dermis (at depths of 100 μm or greater), circular flaps of epidermis (distinguished by Langerin EGFP expression) were observed that superimposed with TR-dextran of the needle shaft, consistent with propulsion of the epidermis into the dermis at the entry site (Fig.  4A , Top and Bottom). Perforation of the epidermis was rapidly reduced, ostensibly reflecting skin retraction within 20 min, coincident with diffusion of the TR-dextran needle cargo into the surrounding epidermis (Fig. 4B) within 24 h did not reveal any colocalization of GFP-bearing LCs and TR-dextran in the vicinity of a needle entry point or in more distal zones, or detectable movement of LCs within the epidermis. In contrast, after application of MAs containing TR-dextran to CD11c-diphtheria toxin receptor (DTR)-EGFP reporter mice, CD11c-expressing cells within the dermis were observed to contain small amounts of TR-dextran (Fig. 4C, Fig. S5 , and Movie S1), indicating acquisition of the MA.
Lang neg DCs Are a Major Population Presenting MHC I-Restricted Ag
After MA Immunization. To probe which DCs contribute to the CD8 + T-cell response primed by live rAdHu5 virus-vectored MA vaccination, we first examined how rAdHu5 MAs applied to the dorsal skin of the foot influenced the relative number and kinetics of skin migrant and LN-resident DCs accumulating in popliteal LNs. FITC-dextran incorporated in the rAdHu5 MA was used as a surrogate for Ag uptake and DC labeling in the setting of virus-induced DC mobilization. Skin-draining low-density enriched LN cells revealed a peak of FITC + CD11c +
MHCII
+ APCs at 48 h after MA application and a second (but reduced) peak at 120 h (Fig. 5A) (Fig. 5D ) and stimulated proliferation of cocultured naïve CD8 + OT-1 T cells in vitro (Fig. S8) . Some presentation by Lang neg LN-resident DCs (in addition to the Lang neg migratory DCs) cannot be completely excluded in these assays based on gating strategy (Fig. S8) To explore the functional in vivo APC requirements for priming naïve CD8 + T cells in the context of rAdHu5-OVA MA immunization, we used C57BL/6 (B6)-CD11c-EGFP-DTR mice that express a GFP-diphtheria toxin receptor (DTR) fusion protein under the control of the CD11c promoter (20) , allowing for conditional ablation of dermal CD11c + cells after DT injection, but retention of LCs, which, although expressing CD11c, cannot be depleted in this model (ref. 21, Fig. 6 ). As expected, the frequency of SIINFEKL-specific CD8 + T cells in spleen after MA immunization was significantly reduced in DT-treated mice when cross-compared with untreated mice (P < 0.05; Fig. 6 ). Conversely, ablation of Lang + cells by DT treatment of B6-Langerin-EGFP-DTR mice, as revealed by depletion of LCs in the epidermis and dermal Lang + DC (Fig. 7) and Lang + DC in draining LN, had a small but not significant impact on CD8 + Tcell priming (P = 0.2789; Fig. 7 ). Therefore, LCs or Lang + DCs are not required to initiate CD8 + T-cell priming by dissolvable live rAdHu5 virus-vectored MAs.
Discussion
Live recombinant Ad and poxvirus vectors hold promise as vaccines against HIV, malaria, and TB (1-3, 22) . However, major technical challenges remain in terms of their delivery and stability for their realization to counter global disease burden. Hence, there is intense interest in technological advances to achieve live vector thermostability coupled with a delivery platform exploiting DC biology to induce potent cellular immunity. Here, we reveal several important technical advances and mechanistic insights. We demonstrate the fabrication of a dissolvable MA containing a live recombinant AdHu5 vector that maintains thermostability and bioactivity, enables facile skin delivery, and evokes multifunctional, cytolytic CD8
+ T-cell responses in mice equipotent to that evoked by conventional needle delivery with live virus vector. Importantly, we have deciphered the contributions of the major DC subtypes in CD8 + T-cell priming by this vaccine platform. Unexpectedly, Lang + CD103 + DC subsets were not required for CD8 + T-cell priming. In fact, we show migratory Lang neg CD103 neg DCs more efficiently presented MHC class I-restricted rAdHu5 vectorderived Ag. Also, CD11c
+ MHCII hi CD8α neg EpCAM neg CD11b + DCs (which are the migratory Lang neg CD103 neg DCs) were fully capable of stimulating naïve CD8 + T cells in vitro. These data suggest migratory/skin-derived Lang neg DC subsets are sufficient for CD8
+ T-cell priming in the absence of Lang + DCs, likely by a direct route of Ag presentation but conceivably also indirectly as cross-dressed Ag, a mechanism of Ag presentation by CD8α − DCs for which there is increasing evidence (23, 24) .
Whereas previous studies cited the capacity of model protein Ags and inactivated or subunit vaccine Ags to prime adaptive immunity via microfabrication technology (6-10), our study has advanced this platform for live Ad vectors. This modality brought additional challenges: maintaining conformation of the rAdHu5 capsid proteins sufficient to enable virus host receptor binding, internalization, and nuclear targeting coupled with integrity of the adenoviral genome to enable transcriptional competence for Ag expression. Slow drying rAdHu5 vectors in a sucrose formulation to a dry state demonstrated no loss in transgene immunogenicity for at least 1 mo after reconstitution, in agreement with a previous report (25) . Crucially, to enable greater practical applicability in the field, we advanced this approach by incorporation of a stabilized rAdHu5 HIV-1 gag vaccine vector within the matrix of a dissolvable MA, thus removing the necessity for vaccine reconstitution and hypodermic needle delivery. Effector CD8 + T-cell responses induced by MA immunization were comparable both in magnitude and functionality (cytokine production and cytolysis) to those achieved by conventional needle injection, including i.d. Moreover, robust CD8 + T-cell responses were also found in gut mucosal tissues and their associated lymphoid tissues. We have not yet defined whether this finding is a function of DCs mobilized by the MA delivery system, or a function of the vector, because it is reported that innate DC programming by rAdHu5 promotes intestinal CD8
+ T-cell recruitment (15, 26) , although likely both mechanisms operate. Nonetheless, the capacity to elicit mucosal CD8 + T cells highlights the potential of the live MA vaccine vector delivery platform to confer protection against mucosal pathogens.
T-cell priming by microfabricated vaccine delivery platforms is attributed to Ag capture and/or presentation by LCs (6, (8) (9) (10) . Indeed, our confocal imaging revealed fluorescent MA cargo distributed within the epidermis and dermis, hence potentially accessible to epidermal resident LCs, and LCs either trafficking through the dermis (27) in vivo cross-presentation of Candida albicans-derived Ag has been reported (13) . Equally, given recent evidence for acquisition of cross-dressed Ag from parenchymal cells (24) + T-cell responses in mice, highlighting an important technical advance to enable the possibility of live vector stability and delivery in a global context. These data may have important implications for recombinant viral vaccine vectors advancing to the clinic and shed light on the early events after MA delivery, indicating a striking redundancy in the role of LCs or Lang + DCs in priming naïve CD8 + T-cell responses and also the possibility that multiple routes of Ag presentation operate after MA vaccination.
Materials and Methods
Full details of methods are described in SI Materials and Methods.
Recombinant E1, E3-Deleted Adenovirus Vaccines. AdHu5-OVA virus encoding a nonsecreted OVA was a gift from M. Zenke (Aachen University, Aachen, Germany). AdHu5 HIV-1 gag [encoding a codon optimized synthetic HIV-1 CN54-gag gene; Geneart] (Fig. S9) is described in SI Materials and Methods. Viruses were propagated by The Native Antigen Company Ltd.
Fabrication of Microneedle Arrays. Arrays were fabricated by a centrifugation casting method using a 1 cm 2 inverted cone-shaped silicone template comprising 44 needles, each 1,500 μm in height and 670 μm in base diameter as detailed in SI Materials and Methods. For DC tracking experiments, MAs contained both rAdHu5-OVA and TR or FITC-labeled dextran.
Immunization of Mice. MAs were applied to the dorsal surface of the foot, the ear, or the back skin of mice. Intravital Confocal Microscopy. TR-dextran MAs were applied to the shaved skin of Lang-EGFP or CD11c-EGFP-DTR mice and imaged.
Reagents for Flow Cytometry. SIINFEKL peptide was purchased from GenScript and HIV-1 gag 309-318 peptide and PE-labeled K b /SIINFEKL pentamer from ProImmune. Allophycocyanin-labeled D b /GVKNWMTDTL tetramer was provided by the University of Washington, Seattle.
Analysis of Polyfunctional CD8
+ T-Cell Responses. Spleen cells were restimulated with anti-CD28 either alone or with OVA 257-264 or HIV-1 CN54 gag 309-318 peptides and stained for IFN-γ, IL-2, and TNF-α or CD107.
In Vivo Killing Assay. Splenocytes were labeled with CFSE at 5 μM (CFSE hi ) or 0.5 μM (CFSE lo ), pulsed with or without HIV-1 CN54 gag 309-318 peptide, then injected into immunized mice and harvested after 15 h.
Statistical Analysis. Bars in figures show the mean ± SEM. A two-tailed Student t test was performed when comparing two different conditions. A oneway ANOVA with a Tukey-Kramer post hoc test were used to analyze three or more conditions. P value <0.05 was considered significant.
